Clinical Trial Update: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing goal achievement with an anti-PCSK9 antibody in statin-intolerant subjects for hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• anti-PCSK9 antibody

Snippet

Sponsor: Amgen | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2018-08-31